GeoVax Labs appointed Shahin Behroyan to its board and named Tyler O’Brien interim chief executive officer and board chairman, marking two leadership changes as the company works toward appointing a permanent CEO. Behroyan’s appointment took effect November 5; O’Brien’s new roles take effect November 8.
- Board changes: Behroyan joins the board after five former directors resigned effective October 23. He was appointed to fill a resulting vacancy and is expected to serve until the next annual stockholders’ meeting, unless he leaves earlier or a successor is elected.
- Behroyan’s background: The 39-year-old Vancouver-based entrepreneur has worked in investments, consumer goods, healthcare and wellness, and market research. GeoVax cited his experience with corporate transactions, acquisitions and financing agreements. He has been CEO of iSpecimen since August 26, 2026.
- Independence and compensation: GeoVax considers Behroyan independent. He has not been assigned to a board committee and will receive the standard compensation paid to the company’s other non-employee directors.
- Interim CEO and chair: O’Brien will serve as interim CEO until a permanent chief executive is appointed or designated. He will also become chairman of the board. The announcement did not provide details about his compensation or a timetable for selecting a permanent CEO.
What changes: GeoVax has added one director following the departure of five board members and assigned both the interim CEO role and board chairmanship to O’Brien. The company remains in a leadership transition, with its permanent CEO still to be appointed.